HUTCHMED (China) (HMDCF) Acquisitions (2019)
HUTCHMED (China)'s (HMDCF) quarterly Acquisitions came in at $8.1 million in Q4 2019.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Acquisitions (2019) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Acquisitions for 1 consecutive years, with $8.1 million the latest figure, recorded in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn | 11.21 Bn |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |